DexCom, Inc. (NASDAQ:DXCM) – Leerink Swann upped their Q4 2018 earnings per share (EPS) estimates for shares of DexCom in a report released on Tuesday, December 4th. Leerink Swann analyst D. Antalffy now anticipates that the medical device company will post earnings per share of $0.09 for the quarter, up from their previous forecast of $0.07. Leerink Swann also issued estimates for DexCom’s Q1 2019 earnings at $0.07 EPS, Q4 2019 earnings at $0.15 EPS, Q1 2020 earnings at $0.24 EPS, Q2 2020 earnings at $0.23 EPS and Q3 2020 earnings at $0.25 EPS.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, November 6th. The medical device company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.29. The business had revenue of $266.70 million during the quarter, compared to analysts’ expectations of $242.72 million. DexCom had a negative return on equity of 2.89% and a net margin of 4.72%. The company’s revenue was up 44.5% on a year-over-year basis.
Other analysts have also recently issued research reports about the company. Jefferies Financial Group upped their price target on DexCom to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Oppenheimer set a $150.00 price target on DexCom and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Canaccord Genuity upped their price target on DexCom from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, August 23rd. Bank of America upped their price target on DexCom from $127.00 to $145.00 and gave the stock a “buy” rating in a research report on Wednesday, August 15th. Finally, BidaskClub cut DexCom from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 18th. Nine equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. DexCom currently has a consensus rating of “Buy” and a consensus price target of $132.65.
Shares of DXCM opened at $129.47 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.71 and a quick ratio of 4.43. The stock has a market capitalization of $11.36 billion, a price-to-earnings ratio of -223.22 and a beta of 0.55. DexCom has a 52 week low of $51.04 and a 52 week high of $152.14.
In other DexCom news, EVP Andrew K. Balo sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $145.17, for a total transaction of $725,850.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Richard Doubleday sold 1,736 shares of the firm’s stock in a transaction that occurred on Friday, November 23rd. The shares were sold at an average price of $121.35, for a total value of $210,663.60. Following the transaction, the executive vice president now owns 66,804 shares of the company’s stock, valued at approximately $8,106,665.40. The disclosure for this sale can be found here. Insiders have sold 149,745 shares of company stock valued at $21,210,998 in the last quarter. 1.80% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Board of Administration of Florida Retirement System grew its holdings in DexCom by 0.4% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 120,747 shares of the medical device company’s stock valued at $11,469,000 after buying an additional 470 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in DexCom by 9.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,552 shares of the medical device company’s stock valued at $527,000 after buying an additional 471 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its holdings in DexCom by 7.6% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 6,879 shares of the medical device company’s stock valued at $653,000 after buying an additional 486 shares in the last quarter. Advisory Research Inc. grew its holdings in DexCom by 17.2% during the 3rd quarter. Advisory Research Inc. now owns 4,084 shares of the medical device company’s stock valued at $584,000 after buying an additional 598 shares in the last quarter. Finally, Oppenheimer & Co. Inc. grew its holdings in DexCom by 23.8% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 3,282 shares of the medical device company’s stock valued at $469,000 after buying an additional 630 shares in the last quarter. Institutional investors and hedge funds own 99.05% of the company’s stock.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.